Trial reportThe American journal of tropical medicine and hygiene2009
Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.
Trial report in The American journal of tropical medicine and hygiene, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.The Journal of infectious diseases · 2015Trial
- Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.The Lancet. Infectious diseases · 2014Trial
- Trial
- Dengue Vaccines.Current topics in microbiology and immunology · 2026Review
- The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Review
- Potential Antivirals: Natural Products Targeting Replication Enzymes of Dengue and Chikungunya Viruses.Molecules (Basel, Switzerland) · 2017Review
- Review
- Recent progress in dengue vaccine development.Virologica Sinica · 2014Review
- Natural products as source of potential dengue antivirals.Molecules (Basel, Switzerland) · 2014Review
- Allosteric inhibition of the NS2B-NS3 protease from dengue virus.ACS chemical biology · 2013Article
- Dengue vaccines: recent developments, ongoing challenges and current candidates.Expert review of vaccines · 2013Review
- Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders.PLoS neglected tropical diseases · 2013Article
- Issues related to recent dengue vaccine development.Tropical medicine and health · 2011Article
- Review
- A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies.Molecular biology reports · 2011Review
- Expression of dengue-3 premembrane and envelope polyprotein in lettuce chloroplasts.Plant molecular biology · 2011Article
- Serologic imprint of dengue virus in urban Haiti: characterization of humoral immunity to dengue in infants and young children.The American journal of tropical medicine and hygiene · 2011Article
- The necessity and quandaries of dengue vaccine development.The Journal of infectious diseases · 2011Article
- Dengue: a continuing global threat.Nature reviews. Microbiology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
rDEN4Delta30-4995 is a live attenuated dengue virus type 4 (DENV4) vaccine candidate specifically designed as a further attenuated derivative of the rDEN4Delta30 parent virus. In a previous study, 5 of 20 vaccinees who received 10(5) plaque-forming units (PFU) of rDEN4Delta30 developed a transient elevation of the serum alanine aminotransferase (ALT) level and an asymptomatic maculopapular rash developed in 10 of 20. In the current study, 28 healthy adult volunteers were randomized to receive 10(5) PFU of rDEN4Delta30-4995 (20) or placebo (8) as a single subcutaneous injection. The vaccine was safe, well-tolerated, and immunogenic. An asymptomatic generalized maculopapular rash and elevations in ALT levels were observed in 10% of the rDEN4Delta30-4995 vaccinees. None of the rDEN4Delta30-4995 vaccinees became viremic, yet 95% developed a four-fold or greater increase in neutralizing antibody titers. Thus, rDEN4Delta30-4995 was demonstrated to be safe, highly attenuated, and immunogenic. However, an asymptomatic localized erythematous rash at the injection site was seen in 17/20 rDEN4Delta30-4995 vaccinees. Therefore, alternative DENV4 vaccine strains were selected for further clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.